arGEN-X, BV: Series B $37M

Posted in I - Series B, Q - 4Q11, R - INTERNATIONAL, X - Antibody, X - Autoimmune, X - Inflammation, X - Oncology, X - Therapeutic Platform

arGEN-X (Netherlands) a preclinical-stage biopharmaceutical company focused on a monoclonal antibody platform for autoimmunity, inflammation and oncology, closed a $37M Series B financing. Participants include Orbimed, Seventure, Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, BioGeneration Ventures, Erasmus MC Biomedical Fund, Thuja Capital Healthcare and VIB.

Jan

2012

SpineGuard, Inc.: Series B $6.2M

Posted in I - Series B, Q - 3Q11, R - INTERNATIONAL, X - Device (Spine)

SpineGuard (France) a commercial-stage medical device company focused on increasing accuracy and efficiency of pedicle screw placement in spine surgery, closed a $6.2M Series B bringing the total financing to $15M. Participants include Credit Agricole Private Equity, Innoven Partenaires, A Plus Finance and Delta Partners.
Thanx for ur patience as we catch-up.

Oct

2011

Amakem, NV: Series A $25.3M

Posted in I - Series A, Q - 3Q11, R - INTERNATIONAL, X - Opthalmology

Amakem (Belgium) a development-stage pharmaceutical company focused on glaucoma and other ophthalmic indications, closed a $25.3M Series A financing. Participants include Forbion Capital Partners, Crédit Agricole Private Equity, Vesalius BioCapital and Life Sciences Research Partners.

Dec

2010

SuperSonic Imagine, SA: Series C $25M

Posted in I - Series C, Q - 4Q10, R - INTERNATIONAL, X - Device (Imaging), X - Device (UltraSound)

SuperSonic Imagine (France) a commercial-stage medical device thearagnotic imaging company focused on the ultrasound visualization and measurement of tissue elasticity, closed a $25M Series C financing. Participants include Edmond de Rothschild Investment Partners, Auriga Partners, Credit Agricole Private Equity, NBGI Ventures, BioAm, Wellington Partners Venture Capital and iXO Private Equity.

Aug

2010

Poxel, SA: Series A $20.3M

Posted in I - Series A, Q - 3Q10, R - INTERNATIONAL, X - Diabetes, X - Metabolism

Poxel (France) a clinical-stage small molecule company focused on Type-2 diabetes and metabolic disease, closed a $20.3M Series A financing. Participants include Edmond de Rothschild Investment Partners, InnoBio Ventures and Crédit Agricole Private Equity.

Feb

2010

CircuLite, Inc.: Series C $32.5M

Posted in I - Series C, Q - 1Q10, R - NORTH EAST, X - Device (Cardiology), XX - NJ

CicuLite (Saddle Brook, NJ) a clinical-stage medical device company focused on minimally invasive implantable devices for chronic heart failure, closed a $32.5M Series C financing. Participants include Forbion Capital Partners, Crédit Agricole Private Equity, Foundation Medical Partners and Oxford Bioscience Partners.

Feb

2010

arGEN-X, BV: Series A $4.5M

Posted in I - Series A, Q - 4Q09, R - INTERNATIONAL, X - Antibody, X - Autoimmune, X - Oncology, X - Therapeutic Platform

arGEN-X (Netherlands) a development-stage biopharmaceutical company focused on a monoclonal antibody platform with potential indications in autoimmunity, oncology and bone disease, closed a $4.5M Series A financing, bring total round proceeds to $18.3M. Participants have included Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, KBC Private Equity, BioGeneration Ventures, Erasmus MC Biomedical Fund, [...]

Jan

2010

BioVex, Inc.: Series F $30M

Posted in I - Series F, Q - 4Q09, R - NORTH EAST, X - Biologics Mfg., X - Oncology, XX - MA

BioVex (Woburn, MA) a clinical-stage biologics company focused on metastatic melanoma, head and neck, pancreatic and colo-rectal cancer, closed a $30M Series F bringing the entire round to $70M. Participants have included Morningside Venture, Ventech, MVM Life Science Partners, Sectoral Asset Management, Ysios Capital Partners, Forbion Capital Partners, Credit Agricole Private Equity, Harris & Harris [...]

to top of page...